Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,226 recruiting studies in this area right now.
By phase
- Not applicable9,543
- Phase 24,410
- Phase 12,677
- Phase 1/Phase 21,654
- Phase 31,397
- Phase 2/Phase 3284
- Phase 4261
Top conditions
- Breast Cancer1,200
- Prostate Cancer645
- Cancer635
- Colorectal Cancer480
- Lung Cancer418
- Ovarian Cancer338
- Multiple Myeloma330
- Pancreatic Cancer290
- Gastric Cancer281
- Acute Myeloid Leukemia280
- Hepatocellular Carcinoma256
- Solid Tumor246
- Advanced Solid Tumor232
- Head and Neck Cancer226
- Cervical Cancer225
- Endometrial Cancer210
- Advanced Solid Tumors203
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University302
- National Cancer Institute (NCI)293
- Memorial Sloan Kettering Cancer Center291
- Sun Yat-sen University275
- Mayo Clinic238
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences143
- AstraZeneca133
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,414
- Texas634
- Arizona507
- Florida437
- Alabama428
- New York406
- Massachusetts342
- Maryland329
- New Jersey273
- Pennsylvania232
Recruiting studies20,226 total
- NCT07363057RecruitingPhase 2
Study of GI-102 and GIB-7 for aging in healthy adults and cancer survivors
This trial tests whether a combination of two drugs, GI-102 and GIB-7, can affect markers of aging in healthy people and in people who have had cancer. It aims to see if these drugs might help slow or improve aging-related changes.
Charlestown, New South WalesAges 18–80 - NCT07369895RecruitingPhase 1
A new cell therapy for relapsed or refractory multiple myeloma
This trial tests a new cell therapy (O&D-001) for multiple myeloma that has returned or not responded to previous treatments. It targets specific markers on myeloma cells (BCMA or GPRC5D) and aims to shrink the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07362186RecruitingPhase 3
LM-108 with Toripalimab vs Paclitaxel for advanced stomach cancer
This trial tests a new combination of two immunotherapy drugs (LM-108 and Toripalimab) against a standard chemotherapy drug (Paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has a specific marker called CCR8. It may be an option if you have already tried a first-line therapy and your cancer has progressed or you had side effects from chemotherapy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07365241RecruitingPhase 3
Study of ABBV-706 vs standard care for advanced small cell lung cancer
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
Birmingham, AlabamaAges 18 years+ - NCT07362888RecruitingPhase 1
Testing a new drug ADCE-B05 for advanced solid tumors
This trial tests a new investigational drug called ADCE-B05 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
Springdale, ArkansasAges 18 years+ - NCT07362459RecruitingPhase 3
Study of SCTB14 for untreated advanced non-small cell lung cancer
This trial tests a new drug, SCTB14, as a first treatment for advanced non-small cell lung cancer that has a high level of PD-L1. It aims to see if the drug is safe and effective for people who haven't had other treatments for their cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07367516RecruitingPhase 1/Phase 2
A new study of TQB6411 for esophageal cancer
This study tests an experimental drug, TQB6411, for people with esophageal cancer that has come back or spread. It may be an option if previous treatments, including immunotherapy and chemotherapy, have stopped working or caused side effects.
Hefei, AnhuiAges 18–75 - NCT06844461Recruiting
Quality of life after acoustic neuroma treatment
This study looks at how acoustic neuroma and its treatments affect your quality of life, and whether you later regret the choices you made. Researchers want to know if follow-up or surgery makes a difference.
BolognaAges 18 years+ - NCT06843707Recruiting
Lung nodule study using blood and tissue metabolism
This trial follows people with lung nodules over time, using blood and tissue samples to look for metabolic changes that may help understand lung cancer better. If you have a lung nodule found on a CT scan and can safely do lung function tests, this study may be a fit.
Guangzhou, GuangdongAges 18–75 - NCT04902846Recruiting
Checking kidney side effects from immune cancer medicines
This study looks at how immune checkpoint medicines (sometimes combined with other treatments like chemotherapy) may affect the kidneys. It may help doctors better prevent or manage kidney side effects in people starting these therapies.
SalamancaAges 18–100 - NCT04785196RecruitingPhase 1/Phase 2
Testing an MDM2 drug plus an immune therapy for advanced tumors
This trial tests APG-115 together with a PD-1 immune therapy in people with advanced liposarcoma or other advanced solid tumors. It may help by blocking tumor growth through a mix of direct tumor targeting and immune system activation.
Guangzhou, GuangdongAges 18 years+ - NCT05461664Recruiting
Avapritinib for advanced GIST without PDGFRA exon 18 changes
This trial studies avapritinib, a targeted medicine, for people with advanced or returning gastrointestinal stromal tumors (GIST) whose tumor does not have PDGFRA exon 18 mutations. It aims to see how well the drug can shrink tumors or control the disease.
GuangzhouAges 18 years+ - NCT05464875Recruiting
Testing avapritinib for advanced GI stromal tumors
This study looks at how well avapritinib works and how safe it is for people with metastatic or unresectable gastrointestinal stromal tumors (GIST). It focuses on whether the tumor has certain marker and gene features and whether you can tolerate related medications.
GuangzhouAges 18 years+ - NCT05098847RecruitingPhase 2
Freezing liver tumors plus anti-cancer drugs for spread cancer
This trial tests whether freezing (cryoablation) liver metastases works better when combined with immunotherapy (sintilimab) and a targeted pill (lenvatinib). It’s for people whose cancer has spread to the liver and has not responded to earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06836505RecruitingPhase 1/Phase 2
CAR-T cell therapy for relapsed neuroblastoma and related tumors
This trial tests a new immune cell therapy (CAR-T) for people whose neuroblastoma or desmoplastic small round cell tumor has returned or not responded to standard treatments. The goal is to see if this therapy is safe and can help shrink or control the cancer.
Guangzhou, GuangdongAges 1–50 - NCT06846905Recruiting
Cost and effects of raising the dose of myeloma drugs at home vs. hospital
This study compares whether raising the dose of your current bispecific antibody is more cost-effective when done as an outpatient (day hospital) or as an inpatient. It aims to find the best way to manage your treatment safely.
ToulouseAges 18 years+ - NCT06847555RecruitingPhase 1/Phase 2
Taurine cream to prevent skin burns from radiation in breast cancer
This trial tests if a taurine cream applied to the skin can prevent or reduce the painful skin reactions caused by radiation therapy for breast cancer. It may offer a simple way to protect your skin during treatment.
Jinan, ShandongAges 18 years+ - NCT06846762Recruiting
DNA/RNA co-testing for advanced lung cancer that has stopped responding to first treatment
This study is for people with advanced non-small cell lung cancer whose tumors do not have certain genetic changes (called driver mutations) and whose first treatment did not work well or caused bad side effects within 6 months. The researchers want to use a special test (DNA/RNA-NGS) to look for hidden genetic alterations that might explain why the cancer didn't respond.
Shanghai, Shanghai MunicipalityAges Any age - NCT04954781RecruitingPhase 2
Chemo plus immunotherapy for advanced bile duct liver cancer
This Phase 2 trial tests whether a procedure called TACE combined with the immunotherapy drug tislelizumab can shrink advanced bile duct liver cancer and help you live longer. It is for people whose cancer cannot be removed and has progressed after at least one prior treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04299581RecruitingPhase 2
Freezing treatment plus immunotherapy for advanced bile-duct cancer
This Phase 2 trial tests whether freezing part of the liver tumor (cryoablation) combined with an immunotherapy drug called anti–PD-1 can shrink advanced bile-duct cancer that can’t be removed by surgery. It may help control the cancer after prior treatments have stopped working.
ShanghaiAges 18 years+ - NCT03957902RecruitingPhase 2
Aspirin blood markers to guide prevention after colon cancer
This Phase 2 trial studies how aspirin affects specific “biomarkers” (measurable body signals) in people newly diagnosed with colon or rectal cancer. The goal is to see whether aspirin-related changes can help design more personalized prevention treatment plans.
Zaragoza, ZaragozaAges 18–79 - NCT05057052RecruitingPhase 2
Freezing liver tumors with immunotherapy and a pill drug
This Phase 2 trial tests whether freezing (cryoablation) plus sintilimab (an immune system medicine) and regorafenib (a pill) can shrink colorectal cancer that has spread to the liver. It is for people whose cancer has come back or progressed after at least two prior chemotherapy treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05020860RecruitingPhase 2
Study how early breast cancer responds on imaging and under a microscope
This Phase 2 study looks at how well early breast cancer shrinks with treatment and how that matches with what doctors find after surgery under the microscope. The goal is to learn better ways to predict and assess treatment success.
Houston, TexasAges 18 years+ - NCT05057845RecruitingPhase 2
Freezing treatment plus immunotherapy and a pill for liver cancer
This trial tests whether freezing (cryoablation) combined with tislelizumab and lenvatinib can help shrink advanced liver cancer and improve outcomes after earlier treatments stopped working or caused side effects. It may be an option if your cancer can’t be removed with surgery and you’ve already tried one prior systemic (whole-body) treatment.
Shanghai, Shanghai MunicipalityAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,226 recruiting oncology studies from the U.S. registry right now, out of 30,453 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.